NCT00193349已完成2 期
Phase II Evaluation of Gleevec Combined With Camptosar Plus Paraplatin in Patients With Previously Untreated Extensive Stage SCLC
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 主要终点
- Response duration
研究概览
简要总结
This study will evaluate combination chemotherapy for patients with extensive stage small cell lung cancer combined with the potentially useful growth inhibiting effects of Gleevec.
详细描述
Upon determination of eligibility, all patients will be receive:
- Irinotecan + Carboplatin + Imatinib
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be included in this study, you must meet the following criteria:
- •Small cell lung cancer with extensive stage disease confirmed by biopsy
- •Measurable or evaluable disease
- •Ability to perform activities of daily living with minimal assistance
- •Adequate bone marrow, liver and kidney
- •No active brain metastasis.
- •No previous chemotherapy or radiation therapy
- •Give written informed consent.
排除标准
- •You cannot participate in this study if any of the following apply to you:
- •Limited stage disease (includes IA, IB, IIA, IIB, and IIIA)
- •Active brain metastasis
- •Age < 18 years old
- •History of a prior malignancy within three years
- •Women pregnant or lactating.
- •Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
结局指标
主要结局
Response duration
Overall response rate
次要结局
- Time to progression
- Overall toxicity
研究者
相似试验
已完成
2 期
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic SyndromesLeukemia, MyeloidMyelodysplastic SyndromesNCT00451997M.D. Anderson Cancer Center10
撤回
2 期
A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid LeukemiaChronic Myeloid Leukemia, Blast CrisisAcute Myeloid LeukemiaNCT00594555University of Cincinnati20
已完成
2 期
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)LeukemiaNCT00955916H. Lee Moffitt Cancer Center and Research Institute38
已完成
2 期
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder CancerBladder Carcinoma Infiltrating the Muscle of the Bladder WallStage II Bladder Cancer AJCC v8Stage II Renal Pelvis Cancer AJCC v8Stage II Ureter Cancer AJCC v8Stage II Urethral Cancer AJCC v8Stage III Bladder Cancer AJCC v8Stage III Renal Pelvis Cancer AJCC v8Stage III Ureter Cancer AJCC v8Stage III Urethral Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8Stage IIIB Bladder Cancer AJCC v8Urethral Urothelial CarcinomaNCT03617913Mayo Clinic2
已完成
2 期
Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung CancerNon Small Cell Lung CancerNCT02716311Intergroupe Francophone de Cancerologie Thoracique118